Published by Josh White on 20th May 2019
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous \'Acarovac MPL\' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.
URL: http://www.digitallook.com/dl/news/story/29055677/...